SAN CARLOS, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company, announced today the closing of its previously announced underwritten public offering of 12,650,000 shares of common stock at a public offering price of $50.00 per share. This includes the exercise in full by the underwriters of their option to purchase up to 1,650,000 additional shares of common stock at the public offering price per share, less underwriting discounts and commissi ...

Fractyl Health ( GUTS ) is developing endoscopic procedures to manage metabolic diseases (obesity and diabetes). The lead candidate is Revita, currently being evaluated in a registrational ph3 trial with topline results expected in 2H 2026, followed byhttps://biotechpharmainvestor.substack.comhttps://x.com/StmkrsBackground: Physician involved in clinical research. Investment style: Clinical-stage biotech stocks, long only, both long-term ideas and event-driven trading. My academic/medical background helps m ...

Avalo Therapeutics Inc.’s (NASDAQ:AVTX) completed enrollment of the Phase 2 LOTUS trial of AVTX-009, the company’s lead drug candidate.The global trial includes approximately 250 adults with moderate to severe hidradenitis suppurativa to evaluate the efficacy and safety of subcutaneous bi-weekly and monthly dosing regimens compared to placebo.Topline data is expected in mid-2026.Analyst TakeCantor hosted Avalo Therapeutics management. Cantor highlights that if the stock fails stock could sink around 85-90%. ...

On Monday, Wave Life Sciences Ltd. (NASDAQ:WVE) said it regained full rights to WVE-006 from GSK Plc (NYSE:GSK) .The update follows agreement with GSK, whose respiratory portfolio is focused on large-scale diseases, that Wave is well placed to advance the WVE-006 program in alpha-1 antitrypsin deficiency (AATD), a rare condition.AATD is an inherited genetic disorder caused by SERPINA1 gene mutations, resulting in low levels of a protective protein (AAT) that leads to severe, early-onset emphysema/COPD and l ...

Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - February 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce the terms of a proposed non-brokered private placement for an aggregate principal amount of up to US$3.0 million of unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). The Company anticipates that the initial closing of the Note Offeri ...

Toronto, Ontario--(Newsfile Corp. - Le 2 février/February 2026) - Mydecine Innovations Group Inc. (MYCO) has announced a name and symbol change to Noveris Health Sciences Inc. (NVRS). Shares will begin trading under the new name and symbol and with a new CUSIP number on February 3, 2026. Disclosure documents are available at www.thecse.com. Please note that all open orders will be canceled at the end of business on February 2, 2026. Dealers are reminded to re-enter their orders. ___________________ ...

Core Viewpoint - Immunovant, Inc. (IMVT) shares have shown a modest gain of 0.4% over the past four weeks, closing at $26, with analysts suggesting a potential upside of 55% based on a mean price target of $40.31 [1] Price Targets and Analyst Estimates - The mean estimate consists of 16 short-term price targets with a standard deviation of $13.5, indicating variability among analysts; the lowest estimate is $16.00 (38.5% decline), while the highest is $57.00 (119.2% increase) [2] - Analysts' price targets can often mislead investors, as empirical research shows that they rarely indicate the actual price direction of a stock [7] - A low standard deviation among price targets suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism regarding IMVT's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has risen by 0.9%, with one estimate moving higher and no negative revisions [12] - IMVT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating a strong potential upside [13] Conclusion on Price Movement - While the consensus price target may not be a reliable measure of potential gains, the implied direction of price movement appears to be a useful guide for investors [14]

Core Viewpoint - Soleno Therapeutics, Inc. (SLNO) has experienced significant selling pressure, resulting in an 18.3% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if SLNO is oversold, with a current reading of 28.79 indicating potential for a trend reversal [2][5] - RSI serves as a momentum oscillator that helps identify price movement changes, suggesting that SLNO may be undervalued due to excessive selling pressure [3] Group 2: Fundamental Analysis - Analysts have raised earnings estimates for SLNO by 7.8% over the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [7] - SLNO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, further supporting the potential for a near-term turnaround [8]

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. One of the twenty stocks on our list of best biotech stocks is Kura Oncology, Inc. TheFly reported on January 13 that Leerink Partners lowered the price target on KURA to $20 from $25 and maintained an Outperform rating. This revision reflects updates to the model incorporating preliminary Q4 financial results, which include Komzifti’s net product revenue, collaboration revenue, and 2026 guidance ahead of the company’s Q4 earn ...

Core Viewpoint - Bristol-Myers Squibb Company (BMY) is set to report its fourth-quarter and full-year 2025 results on February 5, 2026, with consensus estimates for sales at $12.25 billion and earnings per share (EPS) at $1.15. Recent earnings estimates for 2025 have decreased, while those for 2026 have increased slightly [1][4]. Estimate Movement - The current EPS estimates for Q1, Q2, FY 2025, and FY 2026 are $1.15, $1.51, $6.09, and $6.08 respectively, showing a downward trend from previous estimates [2]. - The earnings surprise history indicates that BMY has consistently beaten estimates in the last four quarters, with an average surprise of 20.05% [2][3]. Factors Influencing Q4 Results - BMY's revenue growth is likely supported by its growth portfolio, which includes drugs like Opdivo, Reblozyl, and Breyanzi, despite facing pressure from declining sales of legacy drugs due to generic competition [4][6]. - Opdivo's sales are projected at $2.6 billion, benefiting from label expansions in new indications [7][8]. - Other drugs such as Orencia and Yervoy are also expected to contribute significantly to sales, with estimates of $989 million and $727 million respectively [9]. Legacy Drug Impact - Legacy products accounted for 47% of total sales in the first nine months of 2025, and their decline has negatively impacted overall revenue growth [21]. - Sales from legacy drugs like Eliquis, Revlimid, and Pomalyst are under pressure from generic competition, although Eliquis continues to show strong demand [14][15]. Strategic Collaborations and Acquisitions - BMY's recent acquisition of Orbital Therapeutics adds a promising preclinical RNA immunotherapy candidate to its pipeline, enhancing its capabilities in autoimmune diseases [23]. - The collaboration with BioNTech for the co-development of pumitamig has shown positive interim results, indicating potential in treating various solid tumors [24][25]. Stock Performance and Valuation - BMY's shares have underperformed compared to the industry and the S&P 500, with a current price/earnings ratio of 9.09x, lower than the industry average [17][19]. - The company is viewed as a safe haven for investors in the biotech sector, with a dividend yield of 4.58% providing an incentive to hold shares [26][27].